Scholarlink

<p>Large-scale studies that investigate longitudinal changes in SARS-CoV-2 antibody reactivity in newborn infants are limited. Infants acquire maternal IgG antibodies that decay after birth; if infected, they produce infant-derived IgG, IgA, and IgM antibodies. The New York State Newborn Screening Program (NYS NSP) collects dried blood spots (DBS) from infants at birth and follow-up specimens from a select group of infants, many of whom are premature. We tested 100,318 remnant DBS from 50,036 infants with repeat specimens received between November 2019 and November 2021 for SARS-CoV-2 IgG antibodies; 9611 infants were IgG reactive at birth and 630 seroconverted for SARS-CoV-2 IgG. The first infant seroconversion occurred in March 2020. Infants antibody-reactive at birth were less likely to have low or very low birthweight or be from a multiple birth; infants with repeat specimens were less likely to be reactive at birth than those with single specimens. Antibody decay occurred in a non-linear process with initial rapid decay followed by slower decay (half-life of 22–23&#xa0;days for 0–30&#xa0;days after birth, 37–38&#xa0;days for &gt; 30&#xa0;days after birth). Seroconversion was confirmed by retesting IgG seroconverting infants for detectable IgA and IgM SARS-CoV-2 antibodies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Longitudinal analysis of passively and actively acquired SARS-CoV-2 antibodies in infants with repeat newborn screening samples

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月4日

查看全文
  • Amanda K. Damjanovic,
  • Alexander Keyel,
  • Jean M. Rock,
  • Dylan Ehrbar,
  • Rachel Bievenue,
  • Katherine L. Nemeth,
  • Erica Yauney,
  • Denise M. Kay,
  • Michele Caggana,
  • Monica M. Parker,
  • Linda M. Styer

摘要

Large-scale studies that investigate longitudinal changes in SARS-CoV-2 antibody reactivity in newborn infants are limited. Infants acquire maternal IgG antibodies that decay after birth; if infected, they produce infant-derived IgG, IgA, and IgM antibodies. The New York State Newborn Screening Program (NYS NSP) collects dried blood spots (DBS) from infants at birth and follow-up specimens from a select group of infants, many of whom are premature. We tested 100,318 remnant DBS from 50,036 infants with repeat specimens received between November 2019 and November 2021 for SARS-CoV-2 IgG antibodies; 9611 infants were IgG reactive at birth and 630 seroconverted for SARS-CoV-2 IgG. The first infant seroconversion occurred in March 2020. Infants antibody-reactive at birth were less likely to have low or very low birthweight or be from a multiple birth; infants with repeat specimens were less likely to be reactive at birth than those with single specimens. Antibody decay occurred in a non-linear process with initial rapid decay followed by slower decay (half-life of 22–23 days for 0–30 days after birth, 37–38 days for > 30 days after birth). Seroconversion was confirmed by retesting IgG seroconverting infants for detectable IgA and IgM SARS-CoV-2 antibodies.